ReViral Announces Publication of Article in Journal of Medicinal Chemistry ‘Perspectives’
London, UK, 14th November 2018: ReViral today announced that the article “State of the Art in Respiratory Syncytial Virus Drug Discovery and Development”, written by ReViral’s Dr Stuart Cockerill, Dr James Good and Dr Neil Mathews has been published in the Journal of Medicinal Chemistry ‘Perspectives’. The article is now available at https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01361
Ends
For more information, please contact:
ReViral Ltd
Eddy Littler, CEO
E: elittler@reviral.co.uk
T: +44 (0) 1438 906761
FTI Consulting (PR Advisors to ReViral)
Irma Gomez-Dib (US) +1 212 850 5761
Simon Conway (UK) +44 20 3727 1000
Email: reviral@fticonsulting.com
Notes to Editors
About ReViral
ReViral is a clinical-stage company focused on developing novel, anti-viral compounds that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in route of administration. The lead candidate RV521 completed a Phase IIa study in adult volunteers showing high potency and excellent safety. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In August 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed and Brace Pharma Capital also participated in the fundraise.
About Respiratory Syncytial Virus (RSV)
RSV is a pathogen that infects the human respiratory tract, potentially leading to bronchiolitis and pneumonia. While most (but not all) otherwise healthy people recover from the virus, there is an increased risk of severe disease and death in premature infants, individuals with certain pulmonary conditions, the elderly and those who are immune suppressed. Globally RSV is responsible for more than 30 million infections every year and as many as 200,000 infant deaths. An estimated 2-3% of all infants under 2 years of age are hospitalised with RSV.
About RV521
RV521 is an orally available small molecule antiviral fusion inhibitor being evaluated for the treatment of RSV. RV521 blocks RSV replication by inhibiting RSV F-mediated fusion of RSV to the host cell. In 2018, RV521 generated positive results in a Phase IIa RSV challenge study in healthy adult volunteers, producing statistically significant reductions in viral load and clinical symptoms. In Phase I clinical studies RV521 showed excellent exposure with no serious adverse events. Pre-clinical toxicity tests in adult and juvenile species showed RV521 to have an excellent safety profile with an attractive margin over therapeutic doses.
Source: ReViral Ltd.